Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera

References

• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
   PubMed Web of Science ®Google Scholar
• Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673–683.
   PubMed Web of Science ®Google Scholar
• Larsen TS, Pallisgaard N, Moller MB, et al. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia 2008;22:194–195.
   PubMed Web of Science ®Google Scholar
• Jovanovic JV, Ivey A, Vannucchi AM, et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN & MPNr-EuroNet (COST action BM0902) study. Leukemia 2013;27:2032–9.
   Google Scholar
• Hasselbalch HC, Kjær L, Riley CH, et al. Interferon induces minimal residual disease but not complete molecular remission: Blood. 2013. Available online at: http://www.bloodjournal.org/content/122/6/893.e-letters, accessed 9 September 2013.
   Google Scholar
• Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006;108:2037–2040.
   PubMed Web of Science ®Google Scholar
• Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2006;107:3339–3341.
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761–770.
   PubMed Web of Science ®Google Scholar
• Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997;90:3370–3377.
   PubMed Web of Science ®Google Scholar
• Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 2003;74:26–31.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Rain JD, Bernard JF, et al. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006;32:417–421.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in1980. J Clin Oncol 2011;29:3907–3913.
   Web of Science ®Google Scholar
• Hasselbalch HC, Kiladjian JJ, Silver RT. Interferon alfa in the treatment of Philadelphia–negative chronic myeloproliferative neoplasms. J Clin Oncol 2011;29:e564–565.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. A new era for IFN-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011;4:637–655.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011;117:4706–4715.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065–3072.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27:5418–5424.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood 2013;122:893–901.
   PubMed Web of Science ®Google Scholar
• Samuelsson J, Mutschler M, Birgegard G, et al. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica 2006;91:1281–1282.
   PubMed Web of Science ®Google Scholar
• Larsen TS, Bjerrum OW, Pallisgaard N, et al. Sustained major molecular response on interferon alpha–2b in two patients with polycythemia vera. Ann Hematol 2008;87:847–850.
   PubMed Web of Science ®Google Scholar
• Larsen TS, Moller MB, de Stricker K, et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009;14:331–334.
   Google Scholar
• Larsen TS, Iversen KF, Hansen E, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res 2013;37:1041–1045.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14–22.
   PubMed Web of Science ®Google Scholar
• Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009;113:4829–4833.
   PubMed Web of Science ®Google Scholar
• Rank CU, Kjær L, de Stricker K, et al. Increasing red cell mass and JAK2 V617F allele burden in a patient with polycythemia vera and normal bone marrow five years after discontinuation of long-term interferon-alpha2b. J Hematol Transfus 2014;2:1019.
   Google Scholar
• Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 2013;6:49–58.
   PubMed Web of Science ®Google Scholar
• Ishii T, Xu M, Zhao Y, et al. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-alpha 2a in a patient with polycythemia vera. Leukemia 2007;21:373–374.
   PubMed Web of Science ®Google Scholar
• Riley CH, Jensen MK, Brimnes MK, et al. Increase in circulating CD4(+)CD25(+)Foxp3(+) T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-alpha. Blood 2011;118:2170–2173.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Masse A, Cassinat B, et al. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia 2010;24:1519–1523.
   PubMed Web of Science ®Google Scholar
• Lippert E, Mansier O, Migeon M, et al. Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis. Haematologica 2014;99:e98–101.
   PubMed Web of Science ®Google Scholar
• Kuriakose E, Vandris K, Wang YL, et al. Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. Haematologica 2012;97:538–542.
   PubMed Web of Science ®Google Scholar
• Silver RT, Vandris K, Goldman JJ. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011;117:6669–6672.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials. A Danish study of low-dose interferon-alpha versus hydroxyurea in the treatment of philadelphia chromosome negative (Ph-) chronic myeloid neoplasms - a national randomized prospective study with focus on efficacy, toxicity and quality of life (DALIAH): Clinical Trials. Available online at: http://clinicaltrials.gov/ct2/show/NCT01387763, accessed 9 September 2013.
   Google Scholar
• Hasselbalch HC. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 2013;24: 133–145.
   PubMed Web of Science ®Google Scholar
• Andersen CL, McMullin MF, Ejerblad E, et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. Br J Haematol 2013;162:498–508.
   PubMed Web of Science ®Google Scholar